Another Patent Granted; PTL

12/3/15: I was granted expanded patent claims on a previous patent of 2012; concerning the treatment of arthritic joints with certain phytochemicals; anthocyanins and anthocyanidins.

8,263,069 Composition including anthocyanins and anthocyanidins for prevention and or treatment of articular cartilage associated conditions. September 11, 2012.

However the requests for a claim for direct intra articular injection was not granted. So after three years and lots of legal expense to contest their ruling we were granted the following claims which means I own the intellectual property for the intra articular injection of a specific and common anthocyanidin, cyanidin-3-glucoside to cause increased growth hormone IGF-1, inhibiting negative cytokine IL-1 which will induce the release of glycoaminoglycoside which in turn provides nutrition and protection to the articular cartilage of the arthritic synovial joint. Furthermore there is the potential to regenerate the damaged cartilage of an arthritic synovial joint.

THE NEW CLAIMS

1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject an intra-articular injection of a composition consisting of an anthocyanin glucose and a pharmaceutically acceptable carrier, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside and said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM.

2. The method according to claim 1, wherein the composition increases gene expression of IGF-l in the arthritic joint.

3. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the arthritic joint of a subject is associated with a chondroprotective effect in the joint of a subject.

4. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside release in the arthritic joint of a subject is associated with a chondronutritive effect in the joint of a subject.

5. A method for treating damaged cartilage, comprising the intra-articular injection of a composition consisting of an anthocyanin glucose and a pharmaceutically acceptable carrier into the arthritic joint of a subject, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM

6. The method according to claim 11, wherein the composition stimulates the production of insulin-like growth factor -1 (IGF-1) in the joint to regenerate the damaged cartilage.

7. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the cartilage, comprising an intra-articular injection of a composition consisting of glucose, and a pharmaceutically acceptable carrier and a anthocyanin, wherein said anthocyanin is cyanidin-3-glucoside, and wherein said glucose is a 5% solution and wherein the cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM.

Comments

comments